Anti-obesity drive, generic drugs to remain key focus in 2026
From changing the definition to the rise of GLP-1 medications, and the government’s several initiatives, especially Prime Minister Narendra Modi's clarion call, obesity became the focus of healthcare in India in 2025.
The anti-obesity drive, especially the generic drugs, will continue to remain a key focus in 2026.
Traditionally, Body Mass Index (BMI) was used to define obesity, but after 15 long years, India revamped its obesity guidelines in 2025 by lowering the threshold for obesity to 25 kg/m² (down from the international 30 kg/m²), with "overweight" defined between 23.0 and 24.9 kg/m².